Iravani Saadi Mahdiyar, Babaee Beigi Mohammad Ali, Ghavipishe Maryam, Tahamtan Maryam, Geramizadeh Bita, Zare Abdolhossein, Yaghoobi Ramin
Hematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Transplant Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
J Cardiovasc Thorac Res. 2019;11(2):132-137. doi: 10.15171/jcvtr.2019.23. Epub 2019 Jun 30.
By aging population, the heart failure and its life-threatening complications have become an enormous issue in public health. Regarding the inflammation as a major contributing pathological factor, the determination of most important inflammatory targets for immunomodulation is a problematic puzzle in the treatment of heart failure patients and the inflammatory pathways primarily involved in different underlying conditions contributing to heart failure can be an area which is worthy of focused research. Considering the dilated cardiomyopathy (DCM) as a relatively high-incident disease leading to heart failure, the aim of this study is to determine the difference in the expression level of interleukin (IL)-6 and IL-18 in patients with ischemic and idiopathic DCM. 39 non-diabetic patients with ischemic and 37 ones with idiopathic DCM were enrolled in the study. 48 healthy individuals were also considered as control group. For quantitative determination of the mRNA expression level of IL-6 and IL-18 genes, an in-house- SYBR Green real-time PCR was used and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was considered as internal control gene. The left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF) was calculated by 2D echocardiographic assessment. Data were finally analyzed via SPSS statistical software version 19.0 using independent t test and 2-∆∆Ct method and <0.05 were considered statistically significant. The IL-6 was significantly higher expressed in patients with ischemic and idiopathic DCM than in healthy controls (274.3 and 168.8 times, respectively, both values <0.001). The same higher expression of IL-18 was observed in ischemic DCM (48.5 times) and idiopathic DCM (45.2 times) compared with healthy individuals (both values <0.001). Both ischemic and idiopathic DCM associates with IL-6 and IL-18 overexpression. However, no significant difference was observed between these two subtypes of DCM in either interleukin expression level. There is certainly need to further studies for evaluating the uniformity of results and also assessing other molecules in determining their roles in pathophysiology and probable utility for management.
随着人口老龄化，心力衰竭及其危及生命的并发症已成为公共卫生领域的一个重大问题。将炎症视为主要的致病病理因素，确定免疫调节最重要的炎症靶点是治疗心力衰竭患者的一个难题，而主要参与导致心力衰竭的不同潜在疾病的炎症途径可能是一个值得重点研究的领域。考虑到扩张型心肌病（DCM）是导致心力衰竭的一种发病率相对较高的疾病，本研究的目的是确定缺血性和特发性DCM患者中白细胞介素（IL）-6和IL-18表达水平的差异。39例非糖尿病缺血性DCM患者和37例特发性DCM患者纳入本研究。48名健康个体也被视为对照组。为了定量测定IL-6和IL-18基因的mRNA表达水平，使用了一种内部SYBR Green实时PCR法，并将甘油醛-3-磷酸脱氢酶（GAPDH）作为内参基因。通过二维超声心动图评估计算左心室舒张末期容积（LVEDV）和左心室射血分数（LVEF）。最终使用SPSS 19.0统计软件通过独立t检验和2-∆∆Ct法对数据进行分析，P<0.05被认为具有统计学意义。缺血性和特发性DCM患者的IL-6表达显著高于健康对照组（分别为274.3倍和168.8倍，两者P值均<0.001）。与健康个体相比，缺血性DCM（48.5倍）和特发性DCM（45.2倍）中也观察到IL-18的相同高表达（两者P值均<0.001）。缺血性和特发性DCM均与IL-6和IL-18的过表达有关。然而，在这两种DCM亚型之间，白细胞介素表达水平均未观察到显著差异。当然，需要进一步研究以评估结果的一致性，并评估其他分子在确定其病理生理学作用和可能的管理效用方面的作用。
